Information from the Department of Health and Social Care (DHSC) regarding the Epanutin 50mg Infatabs supply issue:
Pfizer, the sole supplier of Epanutin (phenytoin base 50mg) Infatabs have experienced global delays in the manufacturing of this product. As a result, they are anticipating an imminent gap in supply until early November 2019 when their next batch arrives. Pfizer has issued a Dear Healthcare Professional letter with detailed information on the issue and management plan see below.
The MHRA has classified phenytoin as a Category 1 antiepileptic drug. In the event that you need to prescribe a product from a different manufacturer then this must be carefully managed and increased monitoring of the patient may be required as clinically relevant differences between different manufacturers’ products might occur. Pfizer have been able to secure supplies of a Canadian phenytoin base Infatabs (brand name Dilantin 50mg Infatabs), which will be available when current supplies of Epanutin Infatabs are depleted. Further information on this is attached and below:
Details on prescribing and ordering
Further information
Dilantin PIL
Epanutin PIL
Dilantin Infatab DHCP letter
Epanutin and Dilantin Images
Want the latest pharmacy news and updates straight to your inbox?
Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.
Sign Up